Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

Abstract

Objective. To evaluate the efficacy of low dose apatinib plus chemotherapy on advanced gastric carcinoma. Methods. Eligible 50 patients with advanced gastric carcinoma admitted to the hospital from January 2019 to March 2020 were enrolled, and they were assigned into the control group ( n = 25 , chemotherapy) and observation group (apatinib plus chemotherapy). Changes of CEA, CA72-4, and VEGF levels were measured, and the efficacy of the two groups was evaluated by referring to KPS and RECIST. Results. Significant reduction was observed in CEA, CA72-4, and VEGF in both groups, and the treatment in the observation group resulted in a greater reduction (all P < 0.05 ). The observation group obtained significantly higher KPS scores of compared with the control group ( P < 0.05 ). In addition, the treatment in the observation group led to a better control rate in relative to the control group according to RECIST the score ( P < 0.05 ). Conclusion. The combination of low dose apatinib and chemotherapy might be a promising option for advanced gastric cancer and it merits clinical application.

Safety and Efficacy of of apatinib combined with chemotherapy in the second-line and subsequent lines of advanced gastric cancer: A systematic review and meta-analysis

“…We searched 1594 studies from 7 databases.Of these studies, 826 duplicate studies were excluded and two reviewers independently assessed the remaining 768 studies to determine their eligibility.Next, a total of 752 studies were excluded due to the following reasons: no control group (286); insu cient data (98); full text unavailable (143); quality assessment exclusion (139); combined PD-1/PD-L1 ( 89).Finally, a total of 13 studies were included [17-29] [17][18][19][20][21][22][23][24][25][26][27][28][29] .The detailed literature search process is shown in Fig. 1.…”

“…The characteristics of the studies nally included in the meta-analysis are shown in (Table 1). The studies were published between 2018 and July 2023, and were all conducted in China.The primary endpoint of this study is ORR and R0 resection rate; the secondary endpoint is DCR; the safety endpoint is any grade of AEs.A total of 1217 patients with advanced GC were included in 13 studies [17][18][19][20][21][22][23][24][25][26][27][28][29] , including 652 patients in the observation group and 565 patients in the control group.The pathological type was adenocarcinoma in 6 studies [17,19,21,25,26,28] , and 7 studies did not describe it [18, 20, 22-24, 27, 29] .Some are located at the gastroesophageal junction [17,25,26] , and the rest are located in the stomach.In the observation group, 9 studies [18,19,21,[24][25][26][27][28][29] used low-dose apatinib (≥ 500 mg qd), and 3 studies [20,22,23] used high-dose apatinib. 1 item [17] is unknown.There are 8 studies using RCT [17, 18, 20-22, 24, 28, 29] .There are 5 studies using retrospective research [19,23,[25][26][27]…”

The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis

“…[5][6][7] Apatinib, a novel TKI and antiangiogenic agent, has shown encouraging efficacy in advanced gastric adenocarcinoma and unresectable HCC. [8,9] In recent years, conclusions regarding the efficacy and safety of apatinib and sorafenib as first-line treatment for advanced HCC in direct comparative studies are still controversial. [10,11] Therefore, this meta-analysis aims to evaluate the efficacy and safety of a new TKI (apatinib) versus a traditional TKI (sorafenib) in the first-line treatment of advanced HCC, including the efficacy and safety differences between these 2 TKIs when combined with TACE, to provide evidence for clinical rational drug use.…”

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study

“…Based on the results of the RAINBOW, ATTRACTION-02 and KEYNOTE-059 clinical trial, antiangiogenic ramucirumab combined with chemotherapy and immunotherapy were approved by the FDA for the secondline and third-line treatment of metastatic gastric cancer (Wilke et al, 2014;Kang et al, 2017;Fuchs et al, 2018), respectively. Some small-sample retrospective studies suggested that antiangiogenic small-molecule multi-targeted tyrosine kinase inhibitors (TKIs) combined with chemotherapy, immune checkpoint inhibitors (ICIs) plus anti-angiogenesis may be potentially effective combination therapy strategies (Gao et al, 2022;Li et al, 2022;Tang et al, 2022). The present study aimed to evaluate the clinical efficacy and safety of chemotherapy, antiangiogenic TKIs + chemotherapy and TKIs + ICIs as second-line or above therapy options for advanced or metastatic gastric cancer.…”

“…Some small-sample retrospective studies suggested that anti-angiogenic small-molecule multi-targeted tyrosine kinase inhibitors (TKIs) combined with chemotherapy, immune checkpoint inhibitors (ICIs) plus anti-angiogenesis may be potentially effective combination therapy strategies ( Gao et al, 2022 ; Li et al, 2022 ; Tang et al, 2022 ). The present study aimed to evaluate the clinical efficacy and safety of chemotherapy, anti-angiogenic TKIs + chemotherapy and TKIs + ICIs as second-line or above therapy options for advanced or metastatic gastric cancer.…”